Efficacy and Safety of Chin Augmentation Using MaiLi-E, a Lidocaine-Containing Cross-Linked Sodium Hyaluronate Gel.

ABSTRACT:

Background

MaiLi-E is a lidocaine-containing cross-linked sodium hyaluronate gel for dermal filling. This prospective, multicenter, randomized, delayed-treatment controlled, evaluator-blinded clinical trial aims to evaluate the efficacy and safety of MaiLi-E for chin augmentation.

Methods

Participants with mild-to-moderate-severe chin retrusion were enrolled and randomized (2:1) to receive MaiLi-E at study onset (MaiLi-E group) or six months later (control group). The primary efficacy endpoint was the response rate of chin retrusion improvement, defined as the percentage of participants whose China (Allergan) Chin Retrusion Scale score improved by ≥1 point from baseline, assessed by independent investigators at Month 6 post-injection for the MaiLi-E group and Month 6 post-ra

SUBMITTER: Xie Y 

PROVIDER: S-EPMC12222339 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature